Breakthrough-Therapy Designation — An FDA Perspective

To the Editor: Recent medical advances, such as targeted therapies for specific tumor genomic defects, checkpoint inhibitors for cancers, and direct-acting antiviral agents for hepatitis C, have led to increasing numbers of potentially important candidate drugs for patients with serious or…

https://ift.tt/2GRpM3S